Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ATOS's Cash to Debt is ranked higher than
85% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ATOS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATOS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: N/A Max: No Debt
Current: No Debt
Interest Coverage No Debt
ATOS's Interest Coverage is ranked higher than
86% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 101.95 vs. ATOS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATOS' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 2
Z-Score: -28.19
M-Score: -683.46
WACC vs ROIC
8.43%
-1000.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 226.24
ATOS's Operating margin (%) is ranked higher than
98% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. ATOS: 226.24 )
Ranked among companies with meaningful Operating margin (%) only.
ATOS' s Operating margin (%) Range Over the Past 10 Years
Min: -637950  Med: -30427.5 Max: 226.24
Current: 226.24
-637950
226.24
Net-margin (%) 291.94
ATOS's Net-margin (%) is ranked higher than
98% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.36 vs. ATOS: 291.94 )
Ranked among companies with meaningful Net-margin (%) only.
ATOS' s Net-margin (%) Range Over the Past 10 Years
Min: -788000  Med: -36645 Max: 291.94
Current: 291.94
-788000
291.94
ROE (%) -207.57
ATOS's ROE (%) is ranked lower than
91% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. ATOS: -207.57 )
Ranked among companies with meaningful ROE (%) only.
ATOS' s ROE (%) Range Over the Past 10 Years
Min: -972.32  Med: -150.83 Max: -136.71
Current: -207.57
-972.32
-136.71
ROA (%) -153.06
ATOS's ROA (%) is ranked lower than
92% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.35 vs. ATOS: -153.06 )
Ranked among companies with meaningful ROA (%) only.
ATOS' s ROA (%) Range Over the Past 10 Years
Min: -7246.67  Med: -149.18 Max: -102.65
Current: -153.06
-7246.67
-102.65
ROC (Joel Greenblatt) (%) -4044.64
ATOS's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.16 vs. ATOS: -4044.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8258.25  Med: -6677.4 Max: -1141.33
Current: -4044.64
-8258.25
-1141.33
Revenue Growth (3Y)(%) -100.00
ATOS's Revenue Growth (3Y)(%) is ranked lower than
100% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.30 vs. ATOS: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATOS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
EBITDA Growth (3Y)(%) 3.50
ATOS's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ATOS: 3.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATOS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.5  Med: 9.1 Max: 54.7
Current: 3.5
3.5
54.7
EPS Growth (3Y)(%) 3.20
ATOS's EPS Growth (3Y)(%) is ranked higher than
57% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ATOS: 3.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATOS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.2  Med: 10.3 Max: 57.3
Current: 3.2
3.2
57.3
» ATOS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

ATOS Guru Trades in

Q4 2015

ATOS Guru Trades in Q4 2015

Jim Simons 109,762 sh (New)
» More
Q1 2016

ATOS Guru Trades in Q1 2016

Jim Simons 272,562 sh (+148.32%)
» More
Q2 2016

ATOS Guru Trades in Q2 2016

Jim Simons 352,262 sh (+29.24%)
» More
» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:LEDIF, NAS:BASI, OTCPK:BZYR, NAS:TBIO, NAS:CBMX, NAS:GBSN, NAS:APPY, OTCPK:MDIT, OTCPK:BTHCF, NAS:BIOC, OTCPK:OXIS, OTCPK:SQIDF, NAS:SGNL, NAS:IDXG, NAS:ROKA, OTCPK:DIGP, OTCPK:BMKDF, NAS:WGBS, NAS:CHEK, NAS:CAPN » details
Traded in other countries:YAG.Germany,
Atossa Genetics Inc is a healthcare company. The Company is focused on improving breast health through the development of a suite of laboratory services, medical devices and therapeutics.

Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.

Ratios

vs
industry
vs
history
P/B 3.78
ATOS's P/B is ranked lower than
57% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.59 vs. ATOS: 3.78 )
Ranked among companies with meaningful P/B only.
ATOS' s P/B Range Over the Past 10 Years
Min: 0.74  Med: 2.92 Max: 22.46
Current: 3.78
0.74
22.46
Current Ratio 1.66
ATOS's Current Ratio is ranked lower than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ATOS: 1.66 )
Ranked among companies with meaningful Current Ratio only.
ATOS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.55 Max: 16.36
Current: 1.66
0.01
16.36
Quick Ratio 1.66
ATOS's Quick Ratio is ranked lower than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ATOS: 1.66 )
Ranked among companies with meaningful Quick Ratio only.
ATOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.55 Max: 16.36
Current: 1.66
0.01
16.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.20
ATOS's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. ATOS: -36.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.7  Med: -39.1 Max: -36.2
Current: -36.2
-45.7
-36.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.00
ATOS's Price/Net Cash is ranked lower than
75% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.00 vs. ATOS: 25.00 )
Ranked among companies with meaningful Price/Net Cash only.
ATOS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.68  Med: 7.75 Max: 390
Current: 25
2.68
390
Price/Net Current Asset Value 25.00
ATOS's Price/Net Current Asset Value is ranked lower than
83% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.40 vs. ATOS: 25.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.49  Med: 6.4 Max: 130
Current: 25
2.49
130
Price/Tangible Book 12.50
ATOS's Price/Tangible Book is ranked lower than
75% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.42 vs. ATOS: 12.50 )
Ranked among companies with meaningful Price/Tangible Book only.
ATOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.46  Med: 5.44 Max: 95.12
Current: 12.5
2.46
95.12
Earnings Yield (Greenblatt) (%) -130.64
ATOS's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.30 vs. ATOS: -130.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -130.64  Med: 3934.8 Max: 19616.2
Current: -130.64
-130.64
19616.2

More Statistics

EPS (TTM) $ -0.43
Beta0.92
Short Percentage of Float1.55%
52-Week Range $0.14 - 1.23
Shares Outstanding (Mil)39.57

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.29 -0.36 -0.19
EPS w/o NRI ($) -0.29 -0.36 -0.19
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics (ATOS) Soars on Distribution Deal, Conn's (CONN) Rating Boosted Feb 09 2015 

More From Other Websites
Atossa Genetics Announces Reverse Stock Split Aug 25 2016
12:01 pm Atossa Genetics announces a reverse split of its common stock at a ratio of 1-for-15,... Aug 25 2016
Atossa Genetics Announces Reverse Stock Split Aug 25 2016
ATOSSA GENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events Aug 23 2016
ATOSSA GENETICS INC Financials Aug 20 2016
Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update Aug 12 2016
ATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 12 2016
Atossa Genetics Announces Second Quarter 2016 Financial Results and Provides Company Update Aug 12 2016
Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference... Aug 10 2016
Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference... Aug 10 2016
Atossa Genetics Settles Litigation With Besins Healthcare Aug 05 2016
ATOSSA GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Aug 05 2016
Atossa Genetics Settles Litigation With Besins Healthcare Aug 05 2016
ATOSSA GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 27 2016
SeeThruEquity Initiates Coverage on Atossa Genetics, Inc. with a Price Target of $1.15 Jun 30 2016
Atossa Genetics Initiates Additional Drug Development Program Jun 07 2016
Atossa Genetics Initiates Additional Drug Development Program Jun 07 2016
ATOSSA GENETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 07 2016
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016 May 31 2016
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016 May 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)